12 posts
BPC-157 vs TB-500: Which Is Right for You?
BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharmacies.
Oct 2, 2026Epithalon vs Vilon: Which Is Right for You?
Comparing Epithalon and Vilon: both have distinct mechanisms, FDA status, and use cases. Read the sections below to decide which may be right for you.
Oct 2, 2026GHK-Cu vs BPC-157: Which Is Right for You?
GHK-Cu is compoundable for topical use only (Category 1); it is a legal option for skin and wound support. BPC-157 is prohibited for compounding and has no FDA approval—it is not a legal option in the US. For legal tissue and skin support, GHK-Cu (topical) is the only one you can use.
Oct 2, 2026Ipamorelin vs GHRP-2: Which Is Right for You?
Ipamorelin is prohibited for compounding with no pathway. GHRP-2 has complex status—Category 1 on 503B for non-injectable, non-nasal routes only; injectable use is not permitted. For legal injectable GH support, neither is a clear option; sermorelin is the compoundable choice.
Oct 2, 2026PT-141 vs Melanotan II: Which Is Right for You?
PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is safe when used as directed. Melanotan II is not FDA-approved, has no legal pathway, and carries significant safety concerns including nausea, flushing, and potential melanoma risk. Do not use Melanot
Oct 2, 2026Retatrutide vs Tirzepatide: Which Is Right for You?
Tirzepatide is the practical choice today: it is a dual GIP/GLP-1 agonist that is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for obesity) and available by prescription now. Retatrutide is a triple GLP-1/GIP/glucagon agonist that produced higher weight loss in its Phase 2 trials (~24% at 48
Oct 2, 2026Semaglutide vs Liraglutide: Which Is Right for You?
Semaglutide and liraglutide are both FDA-approved GLP-1 agonists for diabetes and weight loss. Semaglutide is usually given once weekly (or daily oral with Rybelsus) and tends to produce greater weight loss in trials; liraglutide is daily injection and remains a proven, effective option.
Oct 2, 2026Semaglutide vs Tirzepatide: Which Is Right for You?
Tirzepatide is a dual GIP/GLP-1 agonist and often produces slightly greater weight loss than semaglutide (GLP-1 only) in trials. Both are FDA-approved for type 2 diabetes and obesity. Choice depends on access, cost, and tolerability—many patients do very well on either.
Oct 2, 2026Semax vs Selank: Which Is Right for You?
Semax and Selank are both Russian-origin peptides with moderate evidence from Russian studies. Neither is FDA-approved in the US; Semax has no clear compounding pathway, and Selank's Category 2 nomination was withdrawn. Both are used for cognitive and mood support abroad but are not legal, approved
Oct 2, 2026Sermorelin vs CJC-1295 / Ipamorelin: Which Is Right for You?
Sermorelin is legal to compound (Category 1) and was previously FDA-approved; it is a safe, legal option for growth hormone support. CJC-1295/Ipamorelin combination is not legally compoundable—both components are prohibited—and CJC-1295 has been flagged by the FDA for cardiac risks. For legal GH sup
Oct 2, 2026Thymosin Alpha-1 vs TB-500: Which Is Right for You?
Thymosin alpha-1 (Zadaxin) is approved in many countries for immune modulation but is not FDA-approved in the US; its 503A Category 2 nomination was withdrawn. TB-500 (thymosin beta-4) is prohibited for compounding and is WADA prohibited. Neither is a straightforward legal option in the US for human
Oct 2, 2026Tirzepatide vs Liraglutide: Which Is Right for You?
Tirzepatide (once weekly) typically produces greater weight loss than liraglutide (daily) and is dual GIP/GLP-1 vs. GLP-1 only. Both are FDA-approved for diabetes and obesity. Tirzepatide is often preferred for maximum weight loss; liraglutide remains effective and may suit those who prefer daily do
Oct 2, 2026